CClinicalTrials.gg
Sign In
SuspendedNCT02728336Updated Sep 25, 2026

MRI Assessment of Patient Suitability for Cardiac Resynchronization Therapy (CRT)

An interventional study of Cardiac MRI in Cardiac Resynchronization Therapy and Magnetic Resonance Imaging (MRI), sponsored by NYU Langone Health. Suspended at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Diagnostic

Why this study was suspended
COVID-19

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Nov 2014, registered Mar 2016).
Updated Sep 25, 2026Primary completion movedStudy completion movedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goals of this project are to: 1) explore the potential use of magnetic resonance imaging (MRI) data for improved prediction of response to cardiac resynchronization (CRT), and 2) use the MRI-derived data together with a computer model of the cardiovascular system to study the relative roles of different factors in the mechanical effects of dyssynchrony in failure, and in the response (or lack thereof) to CRT.

02

Conditions studied

  • Cardiac Resynchronization Therapy
  • Magnetic Resonance Imaging (MRI)
03

In context

Lead sponsor

NYU Langone Health is the lead sponsor of 1,391 studies on the registry; 254 are open to participants now.

Of its 227 completed or terminated interventional studies of FDA-regulated products, 191 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Male and female patients ages 18 and over scheduled by conventional criteria (symptomatic impairment of cardiac function with broadened QRS) for clinical CRT procedures at NYULMC.
  • Normal kidney function as determined by GFR levels.

Inclusion Criteria for Controls

  • Normal kidney function as determined by GFR levels
  • No significant cardiovascular disease or risk factors.

Exclusion Criteria:

  • electrical implants such as cardiac pacemakers or perfusion pumps
  • ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants
  • ferromagnetic objects such as jewelry or metal clips in clothing (which will be removed)
  • pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Active comparator
    Heart Failure Patients

    patients who are scheduled to undergo clinically ordered CRT for heart failure complicated by dyssynchrony

    Procedure: Cardiac MRI

  • Active comparator
    Control

    20 matched control subjects

    Procedure: Cardiac MRI

Interventions

  • ProcedureCardiac MRI
06

What researchers measure

Primary outcomes

  1. Derivation of score of patient suitability for CRT

    Binary logistic regression and receiver operating characteristic curve (ROC) analyses will be used to assess the utility of baseline (pre-CRT) MRI-derived measures, alone and in combination, for the prediction of response to CRT.

    Time frame: 4 Years

07

Study locations

1 site
  • New York University School of Medicine
    New York, New York 10016, United States
08

Updates

1 registry update since Sep 25, 2026
Primary completion
Aug 2026→Aug 2028
Sep 25, 2026
Study completion
Aug 2026→Aug 2028
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Primary completion Aug 2026→Aug 2028
    Study completion Aug 2026→Aug 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT02728336
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Apr 5, 2016
Start date
Nov 2014
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Sep 25, 2026

Study contacts

Leon Axel, MD
principal investigator · New York University Medical School

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

NYU Langone Health

Start the discussion